Nov 19, 2021, 19:35 by

Nov 19, 2021, 19:35 by

Clinical Ink today announced it ranked on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. Clinical Ink grew 293% during this period.

Nov 19, 2021, 16:12 by User Not Found

Clinical Research News | Although CDISC standards are clearly helping to expedite the review of submissions, many organizations are completing this compliance step at the end of a clinical trial. The data rework involved in this process requires significant time and resources, particularly as metadata is often held in disparate systems and the evolving standards tend to be implemented manually. Clinical metadata repositories (CMDRs) can be used to embed CDISC standards into the study’s design, build and submission.

Nov 19, 2021, 01:00 by User Not Found

Clinical Research News | Although CDISC standards are clearly helping to expedite the review of submissions, many organizations are completing this compliance step at the end of a clinical trial. The data rework involved in this process requires significant time and resources, particularly as metadata is often held in disparate systems and the evolving standards tend to be implemented manually. Clinical metadata repositories (CMDRs) can be used to embed CDISC standards into the study’s design, build and submission.

Nov 18, 2021, 01:00 by User Not Found

Clinical Research News | Evidence has been mounting for decades that what men eat can lower or raise their risk of prostate cancer—including aggressive forms of the disease that can be lethal. But that’s only part of the story.

Nov 16, 2021, 15:22 by

Thermo Fisher Scientific has announced a series of co-marketing agreements, in addition to a new chromatography system and acquisition, to support scientists in driving their proteomics research forwards.

Nov 16, 2021, 15:22 by

Biotium has announced the release of EvaRuby™ Dye for qPCR and HRM®.

Nov 16, 2021, 15:22 by

Nov 16, 2021, 15:22 by

About Vanessa Biotech Vanessa Biotech (VB) is a biomedical company founded on the desire to “give hope where none existed” by making an impact on healthcare markets often overlooked. Its continually expanding pipeline of innovative pharmaceuticals, medical devices and consumer and public health products reflects the company’s inventive nature and commitment to delivering solutions that increase access to quality care. The company’s flagship product, Shylicine™, is the first-ever drug developed to treat the rare and lethal microvillus inclusion disease. Vanessa Biotech, a University of Connecticut Technology Incubation Program participant, has global offices in Hungary, Spain, and Germany in addition to its Hamden, Conn. corporate campus.

Nov 16, 2021, 15:22 by

Tesis Labs Announces Name Change to Tesis Biosciences

Nov 16, 2021, 15:22 by

Nov 16, 2021, 01:00 by User Not Found

Clinical Research News | Concerted effort was required to ensure equitable inclusion of Black, Indigenous, and People Of Color (BIPOC) communities in COVID-19 vaccine trials—a complete reversal relative to historic norms. It would have been an impossibility without temporarily slowing or halting enrollment of White individuals so that the demographic composition at final enrollment closely mirrored the larger U.S. population.

Nov 15, 2021, 18:02 by User Not Found

Clinical Research News | All of us at Cambridge Healthtech Institute, including the staff of Clinical Research News and the SCOPE conference team, are deeply saddened by last week’s tragic passing of Medidata co-founder Glen de Vries in a small plane crash in New Jersey. Encounters with the clinical trial visionary were always a privilege both for the learning opportunity and because of his especially friendly demeanor.

Nov 12, 2021, 01:00 by User Not Found

Clinical Research News | It’s time for healthcare organizations to open clinical trial options to patients at the beginning of the patient journey, not the terminus.

Nov 10, 2021, 01:00 by User Not Found

Clinical Research News | Cell-based vaccines, initially developed to add speed and scale to pandemic response efforts and reduce dependency on chickens in the vaccine manufacturing process, have over the past few years also shown to be more reliably effective than traditional, egg-based products.

Nov 9, 2021, 16:08 by

Today, IBM Research and Arctoris, an Oxford-based technology company operating a fully automated drug discovery platform, announced they are investigating the application of AI and automation to accelerate closed loop molecule discovery.

Nov 9, 2021, 16:08 by

BioIVT’s ASTERAND® Human Tissue Repository contains clinical data from more than one million biospecimens and can be mined to reveal patterns and relationships in disease etiology and pathology.

Nov 9, 2021, 16:08 by

As we continue to navigate the SARS-CoV2 pandemic and new variants of the virus, there is an urgent need to understand how the disease and collective health responses affect the well-being of the general population. QualityMetric’s recent involvement in ORCHESTRA, an ambitious three-year international COVID research project led by the University of Verona. QualityMetric’s SF-36v2® patient-reported outcome (PRO) survey will be used to quantify the disease’s spectrum of symptoms and the functional health and well-being of patients from their own point of view. QualityMetric, a leading global clinical outcomes assessment (COA) solutions provider and scientific consultancy, is building upon our knowledge of the crisis through several COVID impact research initiatives. What makes this newsworthy: • Funded by the EU under the Horizon2020 ERAvsCORONA Action Plan, ORCHESTRA consists of thirty-seven partners from fifteen countries. • The SF-36v2® will help; quantify patient experiences, predict healthcare utilization and evaluate work productivity and job loss to determine COVID’s economic impact. • Researchers are increasingly using PRO measures to clarify the relationship between community disaster events and health-related quality of life. • PRO health surveys help stakeholders forecast health and economic outcomes from advanced predictive algorithms. The SF-36v2® health survey is one of QualityMetric’s most widely used global COA instruments. The data it collects across eight health domains will help the pan-European cohort take an evidence-based approach to developing recommendations for COVID-19 treatment and public health threat preparation.

Nov 9, 2021, 16:08 by

CRO recognized among extra-large companies for its culture and flexible work environment during the pandemic Research Triangle Park, NC – September 14, 2021 - Rho, a full-service contract research organization (CRO) with a proven track record of drug development success, has been honored as one of the top five 2021 Best Places to Work for companies with more than 350 employees by the Triangle Business Journal (TBJ), a multimedia source for local business news, research, and events in the Raleigh, Durham, Chapel Hill region of North Carolina, where Rho is headquartered. The Best Places to Work Awards is an annual program recognizing companies for creating policies and a work environment that employees value. The results are presented based upon employee survey feedback conducted by TBJ. Rho has won the award eight times since 2012.

Nov 9, 2021, 16:08 by

Force Therapeutics Exceeds 110 Clinical Research Studies Published with Leading Medical Journals and Associations